PE-22-28 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible. PE-22-28 is not fda-approved. investigational research peptide only. As with any research compound, individual responses vary.
Is PE-22-28 Safe?
Safety is the most important consideration with any research compound. PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide with a safety profile established through preclinical research.
Superior TREK-1 inhibition (IC50: 0.12 nM vs 40-60 nM for native spadin) with rapid antidepressant effects in rodent stress models. 4-day onset compared to weeks for conventional antidepressants. No human clinical trials.
What Are the Known Side Effects of PE-22-28?
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible.
These effects are based on preclinical data and community reports at standard dosages of 100-500 mcg daily. Higher doses generally increase both the likelihood and severity of side effects.
Are PE-22-28 Side Effects Dose-Dependent?
Most reported PE-22-28 side effects are dose-dependent — meaning they're more likely at higher doses and less likely at the lower end of the 100-500 mcg daily range.
This is why starting at the minimum effective dose and titrating up is the standard approach. With a half-life of 14-23 hours in rodents, any adverse effects will typically resolve within a few half-life periods after discontinuation.
What About Long-Term PE-22-28 Use?
Long-term safety data for PE-22-28 is limited, as with most research peptides. Standard cycles run 4-8 weeks.
PE-22-28 is not fda-approved. investigational research peptide only. Extended use beyond recommended cycles should be approached with caution.
Does PE-22-28 Interact With Other Compounds?
Could theoretically pair with SSRIs for enhanced antidepressant effects through complementary serotonergic mechanisms.
When stacking peptides, be aware that combining multiple compounds increases the total side-effect surface area. Monitor closely when introducing any new compound.
How Can You Minimize PE-22-28 Side Effects?
Start at the lower end of the dosage range (100-500 mcg daily). Use proper reconstitution and injection technique to minimize injection site reactions. Store correctly (lyophilized at -20°C, reconstituted at 2-8°C) to maintain purity.
Source only from vendors with third-party COA testing — contaminated or mislabeled products are a significant source of unexpected adverse effects.
What Is the Bottom Line on PE-22-28 Safety?
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible. Overall, PE-22-28 is considered a compound requiring careful monitoring at standard research doses.
Read our PE-22-28 dosage guide for protocols designed to minimize risk.
Complete Guide
PE-22-28 : Benefits, Dosage, Side Effects & Research
Related Reading
- PE-22-28 Dosage Guide
- PE-22-28 Benefits
- PE-22-28 Stacking Guide
- PE-22-28 Cycle Guide
- PE-22-28 Research
Calculate Your PE-22-28 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PE-22-28.
Open Calculator →Research-Grade Sourcing
If you're going to research PE-22-28, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PE-22-28?
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide. Synthetic shortened analog of spadin with enhanced TREK-1 potassium channel specificity and brain stability. It is researched for rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
What is the recommended PE-22-28 dosage?
Common dosages: 100-500 mcg daily administered once daily via subcutaneous injection (proposed). Cycle length: 4-8 weeks. Half-life: 14-23 hours in rodents. Use our peptide calculator for exact reconstitution math.
What are the side effects of PE-22-28?
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible.
Is PE-22-28 safe?
PE-22-28 has shown a preliminary safety profile in research. Not FDA-approved. Investigational research peptide only. All research should follow appropriate safety protocols.